Literature DB >> 6163946

Production and properties of immune interferon from spleen cell cultures of Toxoplasma-infected mice.

T Shirahata, K Shimizu.   

Abstract

In response to antigenic stimulation, spleen cells from Toxoplasma-infected mice produce a factor showing inhibitory activity against vesicular stomatitis virus infection in L cell cultures. When BALB/C and ICR mice were inoculated intraperitoneally with the low-virulent S-273 strain of T. gondii, such activity was first detected in 4 and 7 days and reached maximum levels at 10 and 14 days respectively, and retained these levels for at least three weeks. However, BALB/C mice, which are considerably more sensitive to Toxoplasma infection than ICR mice, produced significantly smaller amounts of interferon (IF) after challenge with the high virulent strain. The IF produced in this system possessed certain known properties of immune (type II) IF and was not neutralized by rabbit antiserum against mouse type I IF. The immune IF preparation also inhibited multiplication of Toxoplasma within nonphagocytic L cells in an IF-like fashion, whereas Newcastle disease virus-induced (type I) IF had no effect on this parasite. The antiviral and anti-Toxoplasma activity in immune IF preparations could not be distinguished solely on the bases of their molecular weight and isoelectric point. The experiments with anti-theta serum plus complement and with nylon wool column effluent cells strongly suggest that immune IF was produced by T lymphocytes and required the assistance of macrophages.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6163946     DOI: 10.1111/j.1348-0421.1980.tb02915.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  20 in total

1.  Protection of nude rats against Toxoplasma infection by excreted-secreted antigen-specific helper T cells.

Authors:  V Duquesne; C Auriault; F Darcy; J P Decavel; A Capron
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

2.  Decreased production of interferon-gamma by human neonatal cells. Intrinsic and regulatory deficiencies.

Authors:  C B Wilson; J Westall; L Johnston; D B Lewis; S K Dower; A R Alpert
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

3.  Specific and nonspecific mediation of protective immunity to Toxoplasma gondii.

Authors:  L Reyes; J K Frenkel
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

4.  Lymphokine-induced inhibition of growth of Eimeria bovis and Eimeria papillata (Apicomplexa) in cultured bovine monocytes.

Authors:  C A Speer; D W Reduker; D E Burgess; W M Whitmire; G A Splitter
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

5.  Specific mediation of cellular immunity to Toxoplasma gondii in somatic cells of mice.

Authors:  M Chinchilla; J K Frenkel
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

6.  Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan.

Authors:  E R Pfefferkorn
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Interferon-gamma inhibits growth of Coxiella burnetii in mouse fibroblasts.

Authors:  J Turco; H A Thompson; H H Winkler
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

8.  CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice.

Authors:  S J Parker; C W Roberts; J Alexander
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

9.  Comparison of the properties of antirickettsial activity and interferon in mouse lymphokines.

Authors:  J Turco; H H Winkler
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

10.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.